Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Durect Reports Positive Phase IIb Results For Posidur In Post-Op Hernia Pain

This article was originally published in The Pink Sheet Daily

Executive Summary

Posidur, co-developed with Nycomed, has the potential to become a more than $2 billion opportunity, Durect CFO tells “The Pink Sheet” DAILY.

You may also be interested in...



Remoxy NDA Set For Q2 Following Positive Phase III Results

Oradur technology could make the oxycodone product less susceptible to abuse and differentiate it in the market, Durect CEO Brown tells the DAILY.

Remoxy NDA Set For Q2 Following Positive Phase III Results

Oradur technology could make the oxycodone product less susceptible to abuse and differentiate it in the market, Durect CEO Brown tells the DAILY.

Durect and Nycomed To Collaborate On Anesthetic Posidur In $202 Mil. Deal

Durect expects to add 100 to 150 sales reps to market the drug in the U.S.

Topics

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel